Novo Nordisk India launches world’s first and only GLP-1 RA, oral semaglutide
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
They will commercialize molnupiravir in the international markets
He holds nine US patents and has published in multiple peer-reviewed journals and conferences
Krivida Novus can detect the Omicron variant and its sub-lineages in 45 minutes
It provides Covid-19 detection and Omicron surveillance in less than two hours
Prof Karikó's research was most notably used by Pfizer/BioNTech and Moderna to build COVID-19 mRNA vaccines
Results from the BiologyWorks k(now) molecular test were 99.1% in overall percent agreement with the results of the RT-PCR lab tests
The tele-heath market in India is expected to touch US $ 5.4 billion by 2025 and the adoption of tele-health has accelerated with the onset of Covid-19 in 2020. We caught up with Jeya Kumar, Founder and MD, RaphaCure, a prominent player in this segment and he outlined the opportunities that lie ahead for this segment
Occupancy is expected to be in the range of 60-62% while Average Revenue Per Occupied Bed (ARPOB) is expected to expand by least 6% in FY2022
Three Indian firms namely Curisin, Immunidex and Telemedicine Indian company are part of the first phase
Subscribe To Our Newsletter & Stay Updated